United Kingdom · Question · Written question
UIN 73826
Voluntary Scheme for Branded Medicines Pricing and Access
Original
Introduced
14 July 2020
Last action
20 August 2020 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
20 August 2020
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the limit on spending on branded health service medicines under the Voluntary Scheme for Branded Medicines Pricing and Access.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
14 July 2020
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the limit on spending on branded health service medicines under the Voluntary Scheme for Branded Medicines Pricing and Access.
Source: Commons
20 August 2020
Answer
The 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) sets a limit of 2% per year on allowed growth in sales of branded medicines to the National Health Service for the duration of the scheme.The Department holds a six-monthly operatio...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2020-07-14/73826
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1224331
- uk · wq-1224331 · source updated 20 August 2020